24MAY

CEPI rescues Moderna H5N1 vaccine trial

2 min read

16:06UTC

CEPI committed $54.3m to keep Moderna's Phase 3 mRNA H5N1 vaccine trial alive after the US health department scrapped its funding.

← Back to Ebola triples, response misfires Jump to analysis ↓

ScienceDeveloping

Key takeaway

CEPI is now funding the leading bird-flu vaccine trial that US federal money abandoned mid-stream.

The Coalition for Epidemic Preparedness Innovations (CEPI) committed $54.3 million to keep alive Moderna's Phase 3 trial of its messenger-RNA (mRNA) H5N1 vaccine after the US Department of Health and Human Services scrapped the federal funding ¹. First participants were dosed on 21 April , and the candidate, mRNA-1018, is the furthest any mRNA H5N1 vaccine has reached ². H5N1 is the avian influenza strain whose spread through dairy cattle and poultry has kept pandemic planners watching.

The rescue is the same retreat-and-backstop pattern visible at the US border and in the thinned-out Ituri response: a US withdrawal from a pandemic-preparedness commitment, absorbed by a multilateral body. CEPI did not fund this trial originally; it stepped into a gap created by a policy decision, which leaves the world's leading bird-flu vaccine candidate dependent on whoever is willing to cover the cost after the largest single funder leaves.

Deep Analysis

In plain English

H5N1 is the bird flu strain that has been spreading in US dairy cattle since 2024. Scientists have long worried that if it mutates to spread easily between people, it could cause a severe pandemic. Moderna, a US vaccine company, developed an mRNA-based H5N1 vaccine candidate called mRNA-1018 using the same technology platform as the Covid-19 vaccines. It is now in Phase 3, the large-scale human trial that tests whether a vaccine is safe and effective before it can be approved. CEPI, the Coalition for Epidemic Preparedness Innovations (a global partnership funded by governments and charities), committed $54.3 million to keep the trial running after the US government's health department pulled its funding. First participants were dosed on 21 April 2026. This trial matters because if H5N1 did cause a human pandemic, an already-tested mRNA vaccine could be adapted and produced far faster than a traditional egg-based vaccine.

Source Landscape

This story draws on neutral-leaning sources

Consensus view: CEPI's 100 Days Mission framework, which aims to have a vaccine in Phase 3 trial within 100 days of a declared pandemic threat, is being tested in real time by the mRNA-1018 commitment: CEPI's $54.3 million fills the gap left by HHS withdrawing US government funding, but the dependency is now on a single Coalition funder rather than the distributed public-private architecture that produced COVID-19 vaccines at speed.

First dosing on 21 April and Phase 3 continuation to completion represents the furthest any mRNA H5N1 candidate has reached.

Counter-view: The Pasteur Network's regulatory capacity programme, which CEPI expanded via a 21 April 2026 partnership , argued that the mRNA-1018 trial's value is contingent on regulatory capacity in potential pandemic-affected countries: if H5N1 achieves efficient human-to-human transmission in Southeast Asia or Latin America, those countries' regulatory agencies would need expedited review pathways to authorise the vaccine for emergency use.

Those pathways still do not exist in most middle-income countries, regardless of how fast CEPI can manufacture doses.

Key tension: Whether a Phase 3 trial result obtained under CEPI funding, without US government co-ownership, can be leveraged into rapid FDA Emergency Use Authorisation and simultaneous WHO Emergency Use Listing: the two regulatory gates that would determine actual deployment speed in a pandemic.

Sources:Coalition for Epidemic Preparedness Innovations

Mentions:H5N1 →United States →Phase 3 →Pasteur Network →Coalition →Washington →World Health Organization →Moderna →CEPI →

First Reported In

Update #4 · Ebola triples, response misfires

Coalition for Epidemic Preparedness Innovations· 24 May 2026

Read original →

Causes and effects

Caused by

Moderna begins Phase 3 H5N1 mRNA trial

CEPI's $54.3m commitment rescues the Moderna Phase 3 trial that began dosing on 22 April after CEPI's original announcement.

Occurred 22 Apr 2026

Read story →

This Event

CEPI rescues Moderna H5N1 vaccine trial

A multilateral coalition is now financing the furthest-advanced bird-flu vaccine that Washington walked away from.

Different Perspectives

Germany (evacuation recipient)

Germany received the Bundibugyo outbreak's third international medical evacuation on 13 July, a US humanitarian worker infected in Bunia on 10 July. The evacuation, following a French doctor's 24 June departure and May's first US case, tests whether isolation and biocontainment protocols scale beyond DR Congo's own borders.

Pennsylvania Department of Public Health

PDPH retested and retracted a false-positive measles wastewater signal on 6 July, then confirmed and publicised a real airport exposure from 4 July, with commissioner Palak Raval-Nelson stressing there is no broad threat to the general public. The national count, 2,231 cases across 42 states by 9 July, is on pace to beat 2025's 2,289-case record before September.

World Health Organization

WHO published its first dedicated Blueprint on fungal disease and antifungal resistance on 1 July, estimating more than 300 million people suffer serious fungal disease annually. The Blueprint names the gap in WHO's own AMR strategy rather than waiting for an external audit to force the admission.

Africa CDC

Africa CDC issued a formal 11 July appeal for responder protection, training and psychosocial support after health-worker infections tripled from 34 to 112 in a month. The appeal repeats June's unmet call for a rapid Bundibugyo diagnostic test, showing the ask has shifted from tools to basic safety and pay.

Front-line health workers, Ituri Province

Health workers in Ituri Province walked off the job or threatened to strike over unpaid hazard pay and delayed salaries, even as responder infections tripled to 112 with 35 dead. Their absence narrows the isolation workforce the CDC's model says must reach 70% coverage to avoid a 20,000-case worst case.

ECDC

ECDC co-published the isolation and contact-tracing figures behind WHO's DON612, tracking Ituri's isolation rate rising from 35 to 44 percent while still rating EU/EEA import risk as very low. Brussels backs the WHO line against travel restrictions, the position France's own contact-tracing response, not the US entry ban, actually validated.